Development of dPCR-based molecular MRD for acute myeloid leukemia
About the session
Measurable residual disease (MRD) is the most important post-treatment predictor of outcome in patients with adult myeloid leukemia (AML). While flow cytometry-based methods for MRD detection are well-established clinically, molecular methods of MRD detection are still in research development. The use of digital PCR for highly sensitive monitoring of AML-associated mutations in patients on a variety of treatment plans will be discussed, as well as its predictive value for relapse. Bone marrow and cell-free DNA-based MRD will be explored. We will also demonstrate the value of multiplexing assays for simultaneous detection of multiple mutations in limiting patient samples.
Speakers
![Amanda C. Winters](/%5E%5Ecdi={B97DE005-4A20-4B74-A750-B6AD53DCC278}%5Ehash=/-/media/project/qiagen/qiagen-home/service-and-support/learning-hub/virtual-events/innovation-forum-2022/amanda-c-winters.jpg)
University of Colorado, USA.
Dr. Amanda Winters is an Assistant Professor of Pediatrics at the University of Colorado and Children's Hospital Colorado. As a clinician, she treats children and adolescents diagnosed with leukemias and lymphomas. Her primary research focuses on developing high-sensitivity mutation-based measurable residual disease assays for children and adults with acute myeloid leukemia. She is also interested in preclinical validation of candidate targeted therapies to improve outcomes in pediatric AML.